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In this trial, acute myeloid leukemia patients (pts) aged 61–80
years received MICE (mitoxantrone, etoposide and cytarabine)
induction chemotherapy in combination with different sche-
dules of granulocyte colony-stimulating factor administration.
Pts in complete remission were subsequently randomized for
two cycles of consolidation therapy: mini-ICE regimen (idar-
ubicin, etoposide and cytarabine) given according to either an
intravenous (i.v.) or a ‘non-infusional’ schedule. Among the 346
pts randomized for the second step, 331 pts received con-
solidation-1 and 182 consolidation-2. A total of 290 events (255
relapses, 35 deaths in first CR) have been reported. The median
follow-up was 4.4 years. No significant differences were
detected in terms of disease-free survival (median 9 vs 10.4
months, P¼ 0.15, hazard ratio (HR) ¼1.18, 95% confidence
interval (CI) 0.94–1.49) – primary end point – and survival
(median 15.7 vs 17.8 months, P¼ 0.19, HR¼1.17, 95% CI 0.92–
1.50). In the ‘non-infusional’ arm grade 3–4 vomiting (10 vs 2%;
P¼0.001) and diarrhea (10 vs 4%; P¼ 0.03) were higher than in
the ‘i.v.’ arm, whereas time to platelet recovery 420109/l
(median: 19 vs 23 days; P¼ 0.02) and duration of hospitalization
(mean: 15 vs 27 days; Po0.0001) was shorter. The ‘non-
infusional’ consolidation regimen resulted in an antileukemic
effect similar to the intravenous regimen, which was less
myelosuppressive and associated with less hospitalization
days.
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Introduction
Results of chemotherapy in elderly patients (pts) with newly
diagnosed acute myeloid leukemia (AML) have been disap-
pointing with complete remission (CR) rates of approximately
50% in most series of unselected pts and median durations of
disease-free survival (DFS) of less than 1 year.1
There is general agreement that some sort of consolidation
treatment should be used in elderly AML pts after reaching CR.
Its intensity, however, is an open question. In young pts, the use
of intensive consolidation chemotherapy with or without
subsequent stem cell transplantation is a general practice
following the favorable results reported by several large
prospective studies.2–4 Strategies used for young pts may induce
excessive risks when applied in older pts. In most studies,
elderly AML pts receive one to three intravenous consolidation
courses with reduced dosages, sometimes followed by pro-
longed maintenance.5–7 In general, prolonged post-remission
therapy does not seem to improve survival compared to short
post-remission consisting of 2–3 consolidation courses only.8 In
view of the high relapse rate in older AML adults, we explored a
non-infusional post-remission therapy.
Non-infusional treatment might enable treatment on an
outpatient basis. The Finnish Leukemia Group published results
of a trial9 using an oral combination of idarubicin, etoposide
and thioguanine in pts older than 65 years of age, who were
unable to receive standard intravenous (i.v.) therapy. The overall
results were not inferior to those usually obtained with different
combinations of i.v. therapy. The duration of hospitalization was
not different from that of standard regimens, suggesting that an
oral regimen may be of value during the consolidation phase, to
avoid the need of hospitalization at that stage of treatment.
In this report, we present the final results of the second
randomization of the AML-13 trial of the European Organization
for Research and Treatment of Cancer (EORTC) and Gruppo
Italiano Malattie Ematologiche dell’Adulto (GIMEMA) leukemia
groups comparing the mini-ICE regimen (idarubicin, cytarabine
(Ara-C), etoposide) given intravenously, (control arm) or orally/
subcutaneously (s.c.) (experimental arm) in pts who reached CR
after standard induction chemotherapy. The aim was to
compare the efficacy and toxicity of these two modalities
during consolidation therapy. The results of the first randomized
question of this trial (value of granulocyte colony-stimulating
factor (G-CSF) administered during and/or after the induction
chemotherapy) have been published elsewhere.10 It appeared
that the CR rate was significantly higher in pts who received
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G-CSF during chemotherapy (58 vs 49%; P¼ 0.009), whereas in
terms of overall survival (OS) and DFS, no significant differences
were observed between the various groups.
Methods
Study design
The AML-13 trial was a randomized phase III study performed in
53 European centers of the EORTC and GIMEMA Leukemia
Groups. The final protocol was approved by the EORTC
Protocol Review Committee and the Ethical Committee of each
participating center. Each patient signed an informed consent
before randomization.
Pts 61–80 years of age with previously untreated de novo or
secondary AML were randomized into four induction arms
consisting of mitoxantrone, cytarabine and etoposide (MICE)
given either alone or in combination with different schedules of
G-CSF administration (Figure 1). Pts entering CR after one or two
cycles of MICE were subsequently randomized for two cycles of
consolidation treatment consisting of a mini-ICE regimen given
according to either an i.v. or a non-infusional schedule.
Idarubicin has been chosen because it is the first anthracycline
available for both oral and i.v. dosing. To select for equivalent
dosages, the bioavailability and pharmocokinetics of the drug in
both routes was based on in vivo studies performed in one of the
participating centers.11 At selected centers, complete responders
61–70 years with a performance status of 0–1 at the evaluation
of consolidation-1 were eligible for a myeloablative chemo-
therapy followed by re-infusion of autologous peripheral blood
stem cells (auto-PBSC) collected at hematologic recovery phase
post-consolidation-1.
The main objective of the second randomization was to assess
the role of ‘non-infusional’ mini-ICE as consolidation compared
to ‘i.v.’ mini-ICE. The primary end point was DFS. Secondary
end points included duration of remission, incidence of death in
CR, duration of survival, toxicity, number of days to hemato-
poietic recovery, duration of hospitalization and duration of i.v.
antibiotics.
Patients
Pts 61–80 years of age with a morphologically confirmed
diagnosis of either untreated de novo or secondary AML, except
for acute promyelocytic leukemia, withX30% blast cells in the
bone marrow were eligible for first randomization. Blast crisis of
chronic myeloid leukemia and leukemias supervening after
other myeloproliferative diseases were excluded. Prior treatment
for secondary myelodysplasia with cytarabine (doses o100 mg/
m2) administered more than 6 weeks before registration was
allowed. Eligibility for second randomization included: first CR
(CR1) after induction; WHO performance status of 0–2; absence
of severe cardiac, pulmonary, neurologic and metabolic
disease; adequate liver and renal function tests; absence of
active infection; and HIV negativity. Informed consent in
accordance with local institutional guidelines and federal
regulations was required of all pts. Eligibility for myeloablative
chemotherapy with auto-PBSC support as second consolidation
course, required in addition age 61–70 years and WHO
performance status of 0 or 1 at evaluation of consolidation-1.
Treatment
Pts received 1 or 2 remission–induction cycles of an i.v. MICE
regimen (mitoxantrone 7 mg/m2 on days 1, 3 and 5; etoposide
100 mg/m2 on days 1–3; Ara-C 100 mg/m2 continuous infusion
on days 1–7). In a first step, pts have been randomized to either
Lenograstim (Granocytes) 150 mg/m2 on days 1–7, days 8–28,
days 1–28 or none. Pts reaching CR were randomized in a
second step for two cycles of consolidation consisting of either
‘i.v.’ mini-ICE (idarubicin 8 mg/m2 i.v. bolus injection on days 1,
3 and 5; etoposide 100 mg/m2 1 h i.v. infusion on days 1–3;
Ara-C 100 mg/m2 continuous infusion on days 1–5) or ‘non-
infusional’ mini-ICE (idarubicin 20 mg/m2 orally (after break-
fast), in capsules of 5, 10 or 25 mg, on days 1, 3 and 5; etoposide
100 mg/m2 orally, twice daily (after breakfast and dinner), on
days 1–3; Ara-C 50 mg/m2 s.c., twice daily, on days 1–5). Oral
idarubicin (Zavedoss) was supplied by Pfizer bv, Rivium
Westlaan 142, LD Capelle a/d IJssel, The Netherlands. Drug
delivery was performed by each local center using locally
developed patient friendly forms.
Details of the treatment and results of those pts receiving high-
dose chemotherapy (BCNU (N,N-bis[2-chloroethyl]-N-nitroso-
urea), amsacrine, VP-16 and cytosine arabinoside (BAVC)
conditioning regimen) with auto-PBSC support were presented
in part elsewhere.12 Only 18 centers out of 53 chose to perform
auto-PBSCT after consolidation.
Criteria of evaluation
The Cancer and Leukemia Group B criteria for response to
treatment and relapse were used.13 International System for
Human Cytogenetic Nomenclature was applied for cytogenetic
classification.14 Abnormalities 16q(22) and t(8;21) were con-
sidered favorable risk abnormalities, independent of whether
other abnormalities were present or not. Those with a normal
karyotype or with –Y only were classified as intermediate risk.
Those with 5/5q or 7/7q or with complex abnormalities
(43 abnormalities) were considered unfavorable abnormalities.
Pts with other abnormalities were pooled into a separate group
(‘other’). Regarding morphology, the French–American–British
cytological classification has been used.15,16
Toxicity was evaluated according to the National Cancer
Institute (NCI) common toxicity scale. A harvest was considered
successful if X2 106 CD34þ cells/kg could be collected.
Statistical methods
Randomization was performed centrally (EORTC Data Center),
with stratification for center, induction (MICE and no G-CSF vs
MICE and G-CSF days 1–7 vs MICE and G-CSF days 7–28 vs
MICE and G-CSF days 1–28), cytogenetics (good vs intermediate

















*After consolidation-1, patients with age 61-70 years and WHO PS 0-1 were eligible
to receive autoPBSCT instead of consolidation-2
Figure 1 AML-13 schema.
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course, using the minimization technique. DFS was calculated
from the second randomization until the date of first relapse or
death in first CR or last date of follow-up (censored observa-
tions). Duration of survival was calculated from second
randomization until date of death (whatever the cause) or last
date known to be alive (censored observations). Duration of
recovery was defined as the time from start of consolidation until
polymorphonuclear cells or platelet recovery; pts without
recovery were censored at day 90.
The aim of the second randomization, ‘non-infusional’ vs ‘i.v.’
administration of mini-ICE was to detect a difference between
the two arms in terms of DFS (main end point) and survival. The
median DFS in the control group (‘i.v.’ arm) was expected to be
10 months and the 2-year DFS rate of approximately 20%. It was
considered that a 10% loss (10 vs 20%) or a 12% increase (20 vs
32%) in the 2-year DFS rate would be of clinical importance.
This would translate into a 3-month decrease or a 4.3 month
increase in median DFS between the ‘non-infusional’ vs ‘i.v.’
arm, corresponding to a hazard ratio (HR) of 1.43 or 0.7. A total
of 255 events (relapses or deaths) were required for detecting a
treatment difference with an 80% statistical power (two-tailed
log-rank test, a¼ 5%).
Actuarial curves were calculated according to the Kaplan–
Meier technique.17 The standard errors (s.e.) of the estimates
were computed using the Greenwood formula.17 The estimates
of the cumulative incidences of relapse and of death in CR1, and
their s.e., were obtained by considering death in CR1 and
relapse as competing risks.18 The differences between Kaplan–
Meier curves were compared by using the two-tailed long-rank
test,17 whereas for the cumulative incidences the Gray test was
used.18 The Cox’s proportional hazards model has been
employed to obtain the estimate and the 95% confidence
interval (CI) of the HR, ratio of the instantaneous event rate in
the ‘non-infusional’ vs the one in the ‘i.v.’ arm.17 The main
analyses regarding the treatment efficacy was based on all pts
randomized, the intent-to-treat (ITT) principle being followed.
Sensitivity analyses were performed by excluding either pts who
did not start treatment allocated by randomization or censoring
the follow-up at time of autoPBSCT. The duration of hospitaliza-
tion and of i.v. antibiotics, and the grade (0, 1–2, 3–4) of
infections were compared using the Wilcoxon test.17 Grade 3–4
toxicities were compared using the Fisher exact two-tailed test.
The Bonferroni adjustment for multiple comparisons (four in
total: nausea, vomiting, diarrhea and infection) indicate that
Pp0.0125 should be considered as significant and
0.0125oPp0.05 as borderline significant. The SAS 8.2 software
(SAS Institute Inc., Cary, NC, USA) has been used for the
statistical analyses.
Results
A total of 757 pts with either de novo (78%) or sAML (22%) from
53 institutions were enrolled in this study between December
1995 and October 2001. In February 2001, the randomization
for the G-CSF question was stopped, as the study reached
required number of pts. Thereafter, all pts received MICE
induction alone, and randomization of consolidation continued,
in order to reach the number of pts for the second question of the
trial. For entire group of pts the median age was 67 years. Four
hundred-five pts (54%) reached CR after one or two cycles for
induction.
A total of 346 pts were randomized for the second step.
Overall, the median age was 67 years (range 60–79). The
baseline characteristics and induction treatments were well
balanced in both groups (Table 1). The median WBC was 7.7
(‘i.v.’) vs 6.2 109/l (‘non-infusional’).
Treatment compliance
Among the 346 pts randomized, 15 (six ‘i.v.’ vs nine ‘non-
infusional’), did not start the assigned treatment owing to
ineligibility (N¼ 7), early relapse (N¼ 2), too high induction
toxicity (N¼ 2), protocol violation (N¼ 3), treatment refusal





No. (%) No. (%)
Age at registration
61 to o70 121 (70) 117 (67)
X70 51 (30) 57 (33)
Sex
Male 90 (52) 85 (49)
Female 81 (47) 87 (50)
Not recorded 1 (1) 2 (1)
WHO PS at registration
0 81 (47) 96 (55)
1 76 (44) 69 (40)
2 15 (9) 9 (5)
Type of AML
De novo 146 (85) 145 (83)
Secondary 26 (15) 29 (17)
FAB subtype
M0 10 (6) 12 (6)
M1 24 (13) 44 (25)
M2 58 (34) 49 (28)
M4 31 (18) 31 (18)
M5 32 (19) 27 (16)
M6 7 (4) 3 (2)
M7 2 (1) 2 (1)
Missing/unknown 8 (5) 6 (4)
WBC ( 109/l) at registration
o25 123 (72) 120 (69)
25 to o100 34 (20) 33 (19)
X100 14 (8) 17 (10)
Not recorded 1 (1) 4 (2)
Cytogenetics
Good 7 (4) 4 (2)
Intermediate 48 (28) 59 (34)
Poor 22 (13) 25 (14)
Other 20 (12) 13 (7)
Failure 36 (21) 33 (19)
Unknown/ND 36 (23) 35 (20)
Induction treatment
MICE control 37 (22) 38 (22)
MICE+G-CSF d1–7 37 (22) 38 (22)
MICE+G-CSF d8–28 42 (24) 41 (24)
MICE+G-CSF d1–28 48 (28) 50 (29)
MICE non-randomized 8 (5) 7 (4)
Response to first induction course
CR 162 (94) 160 (92)
No CR 10 (6) 14 (8)
Abbreviations: AML, acute myeloid leukemia; CR, complete remission;
FAB, French–American–British; G-CSF, granulocyte colony-stimulating
factor; i.v., intravenously; MICE, mitoxantrone, etoposide and cyta-
rabine; ND, not determined; WBC, white blood corpuscles; WHO,
World Health Organization.
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(N¼ 1). Among the remaining 331 pts, who received the
consolidation-1 course (166 ‘i.v.’ vs 165 ‘non-infusional’), 182
(89 vs 93) received a second course of consolidation, 35 (22 vs
13) an autoPBSCT and 114 (55 vs 59) went off-study for different
reasons, essentially owing to toxicity/treatment refusal (N¼ 77)
or relapse (N¼ 37). Among 61 (33 ‘i.v.’ vs 28 ‘non-infusional’)
pts who received G-CSF for mobilization after recovery from
consolidation-1, stem cell harvest was performed in 54 pts, of
whom, 40 (25 ‘i.v.’ vs 15 ‘non-infusional’) had an adequate
harvest. Among these, five pts (three ‘i.v.’ vs two ‘non-
infusional’ pts) have not been transplanted: three relapsed (two
vs one) and two (one vs one) refused further treatment.
In the ‘non-infusional’ arm less pts (73%) received consolida-
tion-1 course without modifications in the dosage/scheduling of
the study drugs as compared to the ‘i.v.’ arm (95%) (Po0.001).
The drug delivery violations were mostly associated with the
twice-daily scheduling of oral etoposide and/or, to a lesser
extent, subcutaneous cytarabine or oral idarubicin (Table 2).
A similar trend was evident during consolidation-2.
Toxicity
The spectrum of maximum non-hematologic toxicity during
both consolidation cycles was quite similar in the two
randomized arms (Table 3). However, severe (NCI grade 3–4)
gastrointestinal toxicity occurred more frequently in pts treated
with the ‘non-infusional’ regimen as compared to the ‘i.v.’
consolidation regimen, regardless of the administration of
prophylactic antiemetics: nausea 9 vs 4% (P¼ 0.08), vomiting
10 vs 2% (P¼ 0.001), diarrhea 10 vs 4% (P¼ 0.03). In contrast,
the grade of infection was higher, in mean, the ‘i.v.’ arm as
compared with the ‘non-infusional’ arm (P¼ 0.01), whereas
grade 3–4 of infections were not significantly different: 26 vs
20% (P¼ 0.25). More pts required i.v. antibiotics in the ‘i.v.’
than in ‘non-infusional’ mini-ICE: 42 vs 26% during consolida-
tion-1, and 48 vs 39% for the consolidation-2. The number of
days of i.v. antibiotics was also longer in the ‘i.v.’ mini-ICE: 10
vs 7 days (Po0.001) for consolidation-1 and 14 vs 6 days
(Po0.001) for consolidation-2.
Duration of pancytopenia and duration of
hospitalization
Platelet recovery (420 109/l) was faster in the ‘non-infusional’
arm after both consolidation-1 (median: 19 vs 23 days; P¼ 0.02)
and consolidation-2 (median: 21 vs 25 days; P¼ 0.003). The
same trend was observed regarding neutrophil recovery
(40.5 109/l) after the consolidation-1 (median: 23 vs 26 days;










No. (%) No. (%) No. (%) No. (%)
Treatment modified
No 158 (95) 121 (73) 82 (92) 68 (73)
Daily dosages 7 (4) 42 (26) 6 (7) 22 (24)
Schedule 1 (1) 1 (1) 1 (1) 3 (3)
Both 0 (0) 1 (1) 0 (0) 0 (0)
Reason of modification
Unknown 0 (0) 3 (2) 0 (0) 1 (1)
Non-hematological toxicity 1 (1) 0 (0) 3 (3) 2 (2)
Non compliance of patient 0 (0) 1 (1) 1 (1) 1 (1)
Mistakea 5 (3) 32 (19) 1 (1) 18 (19)
Other 2 (1) 8 (5) 2 (2) 3 (3)
Idarubicin % dose given
30 to o50 0 (0) 0 (0) 1 (1) 2 (2)
50 to o70 2 (1) 0 (0) 2 (2) 2 (2)
70 to o90 4 (2) 9 (5) 2 (2) 4 (4)
90 to o110 159 (96) 152 (92) 83 (93) 84 (90)
X110 1 (1) 4 (2) 1 (1) 1 (1)
Ara-C % dose given
20 to o50 0 (0) 3 (2) 0 (0) 1 (1)
50 to o70 0 (0) 5 (3) 0 (0) 3 (3)
70 to o90 3 (2) 3 (2) 1 (1) 3 (3)
90 to o110 161 (97) 148 (90) 86 (97) 83 (89)
X110 2 (1) 6 (4) 2 (2) 3 (3)
Etoposide % dose given
20 to o50 0 (0) 7 (4) 0 (0) 5 (5)
50 to o70 1 (1) 9 (5) 2 (2) 5 (5)
70 to o90 2 (1) 8 (5) 0 (1) 4 (4)
90 to o110 163 (98) 138 (84) 87 (98) 77 (83)
X110 0 (0) 3 (2) 0 (0) 2 (2)
Abbreviations: Ara-C, cytarabine; ICE, idarubicin, etoposide and cytarabine; i.v., intravenously.
aSuch mistakes were due to either a misunderstanding of the protocol, particularly on the schedule of oral etoposide (for instance, 50 mg/m2/day
were administered instead of 50 mg/m2 every 12 h), or due to the availability of oral idarubicin in capsule of 5, 10 and 20 mg, which led to under or
over-dosages 410%, as an exact dose adjustment according to body surface area could not be performed properly.
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P¼ 0.09) and after consolidation-2 (median: 24 vs 26 days;
P¼ 0.25).
Pts in the ‘non-infusional’ arm had a significantly shorter
duration of hospitalization as compared to those in the ‘i.v.’ arm
during consolidation-1 (mean: 15 vs 27 days; Po0.0001),
consolidation-2 (mean: 13 vs 26 days; Po0.0001) and during
both (mean: 24 vs 51 days; Po0.0001).
DFS and survival
The median follow-up was 4.4 years (range 0–7 years). Out of
the 346 pts randomized, on an ITT basis, including the 35 pts
who underwent bone marrow transplantation and the 15 pts
randomized, but not treated, a total of 290 events have been
reported: 255 relapses (136 ‘non-infusional’ arm vs 119 ‘i.v.’
arm) and 35 deaths in CR1 (15 vs 20); a total of 264 pts (138 vs
126) have died.
Regarding DFS, the primary end point of this study, the
difference between the two treatment groups was not significant
(P¼ 0.15), the HR was 1.18, 95% CI 0.94–1.49, the median
estimate was 9 months (‘non-infusional’) vs 10.4 months (‘i.v.’)
(Figure 2). The 3-year DFS rate was 13% (s.e.¼ 3%) vs 21%
(s.e.¼ 3%). The 3-year cumulative incidence of relapse was
79% (s.e.¼ 3%) in the ‘non-infusional’ arm vs 67% (s.e.¼ 4%)
in the ‘i.v.’ (P¼ 0.06), and the 3-year cumulative incidence of
death in CR1 was 8% (s.e.¼ 2%) and 12% (s.e.¼ 3%)
respectively (P¼ 0.33).
Using the Cox model, the treatment comparison of the two
arms in terms of DFS adjusted for cytogenetics (good,
intermediate, other, poor, failure and unknown), type of disease
(de novo vs secondary AML) and sex, remained unchanged:
HR¼ 1.17 (95% CI 0.93–1.48), P¼ 0.19. Other variables had no
prognostic impact. Treatment adjustment for the dose of
etoposide (o vs X90% of the required dose) had no real
impact on the comparison (data not shown).
Similarly, there was no significant (P¼ 0.19) difference in the
OS, the HR was 1.17 (95% CI 0.92–1.50), median was 15.7
months in the ‘non-infusional’ vs 17.8 months in the ‘i.v.’ arm
(Figure 3). The 3-year survival rates were 25% (s.e.¼ 3%)
and 30% (s.e.¼ 4%) respectively. Using the Cox model,
the treatment comparison adjusted for cytogenetics, type of
disease and sex, yielded a HR of 1.12 (95% CI 0.88–1.44),
P¼ 0.35.
Among 35 pts who were transplanted in CR1, 22 relapsed and
five died in CR1. By censoring the follow-up at time of
transplantation, treatment comparisons in terms of DFS and
survival remained essentially unchanged (data not shown). The
exclusion of 15 pts who did not start the randomized treatment
had no impact on treatment comparisons either.
For the 405 pts who reached CR, median DFS was 9 months
and the 3-year DFS rate was 18%, and for survival from CR, it
was 17.5 months and 27% respectively. For all 757 pts
registered in this study median survival was 9 months and the
3-year survival rate 17%.
Table 3 Maximum side effects during/after consolidation-1 and -2 by treatment arm in the per-protocol treatment population
Type ‘i.v.’ mini-ICE (n¼ 166) ‘Non-infusional’ mini-ICE (n¼165)
Grades 1–4 Grades 3–4 Grades 1–4 Grades 3–4
No. (%) No. (%) No. (%) No. (%)
Gastrointestinal
Nausea 98 (59) 7 (4) 107 (65) 15 (9)
Vomiting 69 (42) 3 (2) 80 (48) 17 (10)
Diarrhea 65 (39) 6 (4) 75 (45) 16 (10)
Stomatitis oral 75 (45) 8 (5) 64 (39) 8 (5)
Body as a whole
Infection 108 (65) 43 (26) 84 (50) 33 (20)
Headache 26 (16) 1 (1) 21 (13) 0 (0)
Other flu-like 7 (5) 1 (1) 11 (7) 1 (1)
Rigors/chills 21 (13) 1 (1) 10 (6) 0 (0)
Bone pain 10 (6) 1 (1) 9 (6) 0 (0)
Hematological
Hemorrhage 55 (33) 2 (1) 48 (29) 4 (2)
Prothrombin time 5 (3) 0 (0) 12 (7) 0 (0)
Fibrinogen 7 (4) 0 (0) 6 (4) 0 (0)
Hepatic
Any 34 (20) 9 (5) 33 (20) 10 (6)
Cardiovascular
Edema 15 (9) 0 (0) 22 (13) 1 (1)
Hypotension 17 (10) 3 (2) 19 (12) 6 (4)
Dysrhythmias 13 (8) 1 (1) 13 (8) 4 (2)
Cardiovascular function overall 4 (4) 1 (1) 9 (5) 3 (2)
Genitourinary
Any 18 (11) 0 (1) 19 (12) 1 (1)
Skin
Rash/itch 34 (20) 2 (1) 18 (11) 1 (1)
Abbreviations: ICE, idarubicin, etoposide and cytarabine; i.v., intravenously.
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AML is predominantly a disease of the elderly; the median age at
presentation is 64 years, and 60% of all cases are over 60
years.19–21 AML is a dismal diagnosis in older pts because most
pts are not fit enough for intensive therapy. Usually, therapy
results in low CR rates, high treatment-related toxicities, short
relapse-free and OS.22 The optimal management strategy is a
controversial issue with opinions frequently polarized between
low and high-intensity remission induction. Areas of controversy
include the importance of consolidation and maintenance
chemotherapy as well.
This randomized phase III trial was designed for medically fit
pts 61–80 years of age with untreated de novo or secondary
AML. The results of the first randomized question have been
published elsewhere.10
Pts entering CR after 1 or 2 cycles of MICE were randomized
subsequently for two cycles with mini-ICE for consolidation
given according to either an i.v. or an oral/subcutaneous
schedule. The main aim was to detect a difference in median
DFS from 7 to 10 months between the two treatment arms, and
also to determine whether or not consolidation could be given
on an outpatient basis with the intention to improve quality of
life of these pts.
Our data indicate that a ‘non-infusional’ mini-ICE consolida-
tion regimen is associated with an antileukemic effect not
significantly different from that provided by the standard i.v.
schedule. The 3-year DFS rates were similar in the ‘non-
infusional’ and ‘i.v.’ arms, leading to comparable median
estimates (9 vs 10.4 months) and an estimated HR close to
one. Despite a total of 290 events reported in this study,
allowing the detection with an 85% power of a treatment
difference in DFS, which was considered clinically meaningful,
we were unable to detect a statistical difference. Survival was
not significantly different either. It is noteworthy that DSF
and survival results in both groups of the present study
were comparable to those reported for other intensive
treatment regimens in elderly AML pts.2–9,22 This holds also
true when considering all pts who reached CR or all pts
registered.
The toxicity profiles of the two regimens were similar, with
the exception of a higher frequency of gastrointestinal side
effects (nausea, vomiting, diarrhea) associated with the admin-
istration of ‘noninfusional’ regimen.
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O N Number of patients at risk:
139 172 75 37 24 17 8 4




















Logrank test: p = 0.15
Figure 2 DFS by treatment arm. N¼Number of patients in each treatment group. O¼Observed number of events (relapse or death in CR1).
(years)












O N Number of patients at risk :
126 172 111 63 36 25 15 7











Logrank test: p = 0.19
Figure 3 Duration of survival by treatment arm. N¼Number of patients in each treatment group. O¼Observed number of deaths.
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Decreased compliance to the fractionated daily dosing of oral
etoposide and idarubicin, and subcutaneous cytarabine may be
expected for pts randomized to the ‘non-infusional’ arm, since
the supervision of the self administered non-i.v. schedule was
less strict than in the intravenous schedule. Roughly 10% of pts
showed a reduced compliance with the regular twice-daily
intake of oral etoposide. Such reductions occurred also owing to
a misunderstanding of the protocol by the investigators: one
administration instead of two for the drugs, which were
scheduled twice daily (etoposide or Ara-C) rather than once
daily (idarubicin).
Profound thrombocytopenia and neutropenia generally lasted
more than 2 weeks in each treatment arm. The duration of
thrombocytopenia was significantly shorter (3–4 days) after the
‘noninfusional’ regimen, whereas the reduction in duration of
neutropenia (2–3 days) was borderline significant. Given its less
intensive myelosuppressive effects it is not surprising that the
‘non-infusional’ regimen was associated with a reduced mean
grade of infectious complications and less mean number of days
of i.v. antibiotics (reduction of 3 days during consolidation-1
and of 8 days during consolidation-2).
In our study, the duration of hospitalization was
significantly shorter (by 12–13 days) in pts receiving the ‘non-
infusional’ formulation of the mini-ICE consolidation on an
outpatient basis, as compared to those randomized to the i.v.
mini-ICE.
In our trial, we could not detect a significant difference in
terms of DFS between the i.v. and non-infusional consolidation
regimens despite we had adequately powered the trial. The non-
infusional regimen required less hospitalization days as it was
scheduled to be administered at home, unless complications
were noticed. It also required less i.v. antibiotics, as the
observed grades of infection were lower. The duration of
myelosuppresion, particularly thrombocytopenia, seemed also
shorter in the noninfusional arm as compared with the i.v.
arm, although this outcome might had been influenced by
lower treatment applicability. Further modifications of
this non-infusional regimen (e.g. once daily dosing, better
antiemetic support), may probably improve compliance and
decrease the side effects, particularly nausea-vomiting, of the
treated pts.
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